Abstract 2458: Targeting the CXCR3 axis in HER2+ breast cancer to enhance anti-tumor immunity

作者
Anchit Bhagat,Jesuchristopher Joseph,Joshua D. Ginzel,Christopher A. Rabiola,Amy C. Hobeika,Joshua C. Snyder,Herbert Kim Lyerly,Erika J. Crosby
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 2458-2458
标识
DOI:10.1158/1538-7445.am2024-2458
摘要

Abstract Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. The efficacy of immunotherapies for BC is limited, with response rates of <10% for anti-PD-1/PDL1 monotherapy in pre-treated triple-negative breast cancer (TNBC) patients and even lower in subtypes that express human epidermal growth factor receptor 2 (HER2+) and/or hormone receptors. Hence, there is an urgent need to improve immune based strategies for BC. One possible approach to enhance response is the application of intratumoral (IT) immunotherapy utilizing IL-12; a potent pro-inflammatory cytokine that is critical in producing an anti-tumor response. However, systemic delivery of IL-12 has substantial toxicity and localized delivery of protein has insufficient residence time. To circumvent these issues, we have previously reported the efficacy of intratumorally injected plasmid IL-12 (pIL-12-EP) followed by electroporation in a TNBC mouse model and in clinical trials. Following pIL-12-EP, treated tumor expressed genes that were associated with increased CD8+ T cell infiltration, activation, trafficking, antigen presentation, and exhaustion. Single-cell RNA sequencing (scRNAseq) of tumor infiltrating immune cells from treated tumors revealed a striking enrichment of the CXCL9/10/11/CXCR3 family. This CXCR3 axis is upregulated in response to IFNγ production and has been studied extensively in melanoma and NSCLC patients as a potential predictive biomarker for responses to immune checkpoint inhibitors but has not been well characterized in BC. We hypothesized that this axis may be the critical component downstream of pIL-12-EP treatment that is responsible for anti-tumor responses and that targeting it will be effective in other molecular subtypes of BC beyond TNBC. We first evaluated the expression of CXCR3 by tumor infiltrating lymphocytes (TILs) in biopsies of human HER2+ BC. Using a single cell resolution spatial transcriptomic Xenium instrument we find not only expression of CXCR3 by TILs, but can also track the distance and gradients of the chemokine ligands CXCL9 and CXCL10 in this tumor microenvironment. Having confirmed the activity of this axis in human HER2+ BC, we used our well-established spontaneous HER2-driven mouse model to compare treatment of HER2+ tumors with pIL-12-EP or pCXCL9-EP intratumorally. We observed tumor growth inhibition in both treatment groups as compared to control treated tumors. Interestingly, the abscopal effect previously seen with pIL-12-EP was not evident for distant tumors in mice treated with pCXCL9-EP. These data suggest that IT CXCL9 therapies may benefit from combination with a systemic immune activator like a vaccine or immunogenic chemotherapy. Ongoing studies will continue to evaluate ways to better target this axis therapeutically and define clinically active combination therapies. Citation Format: Anchit Bhagat, Jesuchristopher Joseph, Joshua D. Ginzel, Christopher Rabiola, Amy C. Hobeika, Joshua C. Snyder, Herbert K. Lyerly, Erika J. Crosby. Targeting the CXCR3 axis in HER2+ breast cancer to enhance anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2458.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
愉快的松发布了新的文献求助10
1秒前
2秒前
Lucas的应助被vicky采纳,获得10
2秒前
4秒前
5秒前
Hello的应助被满清风采纳,获得10
6秒前
sisisi完成签到,获得积分10
6秒前
开朗的大树完成签到,获得积分10
6秒前
6秒前
烟花的应助被元宝采纳,获得10
7秒前
7秒前
岩岫清风完成签到,获得积分10
8秒前
Akim的应助被科研小白采纳,获得10
8秒前
8秒前
tomatoGG发布了新的文献求助10
8秒前
ksndn完成签到 ,获得积分10
8秒前
腼腆的水蓝完成签到,获得积分10
9秒前
9秒前
chenzhaoyang发布了新的文献求助10
10秒前
白白完成签到,获得积分10
11秒前
萧笙发布了新的文献求助10
13秒前
高大橙发布了新的文献求助10
13秒前
13秒前
sun完成签到,获得积分10
13秒前
14秒前
领导范儿的应助被滴滴滴采纳,获得10
14秒前
14秒前
MAthor完成签到,获得积分10
14秒前
18秒前
18秒前
任66完成签到 ,获得积分10
19秒前
20秒前
21秒前
科研小白发布了新的文献求助10
21秒前
生动的向日葵完成签到,获得积分10
22秒前
海东南发布了新的文献求助10
23秒前
CipherSage的应助被邓金涛采纳,获得10
24秒前
maT发布了新的文献求助10
24秒前
888发布了新的文献求助10
26秒前
一二三发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640